Article: Callisto Announces Availability of Presentation Outlining Drug Development Pipeline and Market Opportunities; Development Programs Include New Drugs to Treat Leukemia and Multiple Myeloma Cancers, and to Fight Biowarfare Threats.

NEW YORK -- Callisto Pharmaceuticals, Inc. (AMEX:KAL)(FWB:CA4), a developer of new drug treatments in the fight against hematological cancers and related diseases, has announced the online availability of an electronic presentation that provides an informative overview of the Company's development pipeline of needed drugs to treat diseases including blood cancers and serious gastrointestinal inflammation, as well as its program to develop drugs to protect against biowarfare agents for use in homeland security applications.

The presentation, available to all interested investors, provides an overview of the multi-million-dollar markets for the Company's drug ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!